The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Fedoruk N.A.

Krasnov Research Institute of Eye Diseases

Current views on pathogenesis and treatment of neovascular glaucoma

Authors:

Fedoruk N.A.

More about the authors

Journal: Russian Annals of Ophthalmology. 2024;140(3): 110‑116

DOI: 10.17116/oftalma2024140031110

Read: 1370 times

Download PDF (RU)
Contact the author
Table of contents

CURRENT VIEWS ON PATHOGENESIS AND TREATMENT OF NEOVASCULAR GLAUCOMA
CURRENT VIEWS ON PATHOGENESIS AND TREATMENT OF NEOVASCULAR GLAUCOMA

To cite this article:

Fedoruk NA. Current views on pathogenesis and treatment of neovascular glaucoma. Russian Annals of Ophthalmology. 2024;140(3):110‑116. (In Russ.)
https://doi.org/10.17116/oftalma2024140031110

Подписка 2026 Вестник офтальмологии (Russian Annals of Ophthalmology)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Neovascular glaucoma is a type of secondary glaucoma characterized by the most severe course, and ranking second among the causes of irreversible blindness. This review summarizes the results of numerous studies devoted to the search for prevention measures and the most effective treatment strategy. The main ways of preventing the development of neovascular glaucoma are timely diagnosis and elimination of ischemic processes in the retina, combined with adequate control of intraocular pressure and treatment of the underlying disease.

Keywords:

neovascular glaucoma
intravitreal anti-VEGF injections
panretinal laser photocoagulation
anterior chamber angle neovascularization
retinal ischemia

Authors:

Fedoruk N.A.

Krasnov Research Institute of Eye Diseases

Received:

01.12.2023

Accepted:

15.12.2023

Close metadata

References:

  1. Barac IR, Pop MD, Gheorghe AI, Taban C. Neovascular secondary glaucoma, ethiology and pathogenesis. Romanian J Ophthalmol. 2015;59(1):24-28. 
  2. Palma C, Kim D, Singh A, Singh A. Neovascular glaucoma. In: Glaucoma, Medical Diagnosis and Therapy. Shaarawy TM, Saunders WB, eds. 2nd ed. Elsevier Health Sciences; 2015. P. 425-433. 
  3. Yang H, Yu X, Sun X. Neovascular glaucoma: Handling in the future. Taiwan J Ophthalmol. 2018;8(2):60-66.  https://doi.org/10.4103/tjo.tjo_39_18
  4. Rodrigues GB, Abe RY, Zangalli C, Sodre SL, Donini FA, Costa DC, Leite A, Felix JP, Torigoe M, Diniz-Filho A, de Almeida HG. Neovascular glaucoma: a review. Int J Retina Vitr. 2016;2:26.  https://doi.org/10.1186/s40942-016-0051-x
  5. Havens SJ, Gulati V. Neovascular Glaucoma. Devel Ophthalmol. 2016;55: 196-204.  https://doi.org/10.1159/000431196
  6. Liao N, Li C, Jiang H, Fang A, Zhou S, Wang Q. Neovascular glaucoma: a retrospective review from a tertiary center in China. BMC Ophthalmol. 2016; 16:14.  https://doi.org/10.1186/s12886-016-0190-8
  7. Biel NM, Siemann DW. Targeting the angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference. Cancer Lett. 2016;380(2):525-533.  https://doi.org/10.1016/j.canlet.2014.09.035
  8. Senthil S, Dada T, Das T, Kaushik S, Puthuran GV, Philip R, et al. Neovascular glaucoma — A review. Indian J Ophthalmol. 2021;69(3):525-534.  https://doi.org/10.4103/ijo.IJO_1591_20
  9. Filippov VM, Petrachkov DV, Budzinskaya MV, Sidamonidze AL. Modern concepts of pathogenesis of diabetic retinopathy. Vestnik oftal’mologii. 2021; 137(5-2):306-313. (In Russ.). https://doi.org/10.17116/oftalma2021137052306
  10. Catrina SB. Impaired hypoxia-inducible factor (HIF) regulation by hyperglycemia. J Mol Med. 2014;92(10):1025-1034. https://doi.org/10.1007/s00109-014-1166-x
  11. Simó R, Carrasco E, García-Ramírez M, Hernández C. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev. 2006;2(1):71-98.  https://doi.org/10.2174/157339906775473671
  12. Kovacs K, Marra KV, Yu G, Wagley S, Ma J, Teague GC, et al. Angiogenic and inflammatory vitreous biomarkers associated with increasing levels of retinal ischemia. Invest Ophthalmol Visual Sci. 2015;56(11):6523-6530. https://doi.org/10.1167/iovs.15-16793
  13. Sun Y, Liang Y, Zhou P, Wu H, Hou X, Ren Z et al. Anti-VEGF treatment is the key strategy for neovascular glaucoma management in the short term. BMC Ophthalmol. 2016;16(1):150.  https://doi.org/10.1186/s12886-016-0327-9
  14. Budzinskaya MV, Plyukhova AA. Future Perspectives for Antiangiogenic Therapy in Retinal Diseases. Ophthalmology in Russia = Oftal’mologiya. 2021;18(3S):638-645. (In Russ.). https://doi.org/10.18008/1816-5095-2021-3S-638-645
  15. Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol. 2007;18(6):502-508.  https://doi.org/10.1097/ICU.0b013e3282f0ca54
  16. Kwong TQ, Mohamed M. Anti-vascular endothelial growth factor therapies in ophthalmology: current use, controversies and the future. Br J Clin Pharmacol. 2014;78(4):699-706.  https://doi.org/10.1111/bcp.12371
  17. Jeganathan VSE, Wardrop D. A paradigm shift in the management of neovascular glaucoma. New Front Ophthalmol. 2016;2(3):119-124.  https://doi.org/10.15761/NFO.1000128
  18. Mitamura Y, Tashimo A, Nakamura Y, Tagawa H, Ohtsuka K, Mizue Y, et al. Vitreous levels of placenta growth factor and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Diabetes Care. 2002; 25(12):2352. https://doi.org/10.2337/diacare.25.12.2352
  19. Tang Y, Yin H, Wang W, Zhang X, Chu N, Li S, et al. Enhancement of lens extraction-induced MCP-1 upregulation and microglia response in long-term diabetes via c-jun, stat1 and ERK. Life Sci. 2020;261:118360. https://doi.org/10.1016/j.lfs.2020.118360
  20. Feldman-Billard S, Larger É, Massin P. Early worsening of diabetic retinopathy after rapid improvement of blood glucose control in patients with diabetes. Diabetes Metab. 2018;44(1):4-14.  https://doi.org/10.1016/j.diabet.2017.10.014
  21. Whitehead M, Wickremasinghe S, Osborne A, Van Wijngaarden P, Martin KR. Diabetic retinopathy: a complex pathophysiology requiring novel therapeutic strategies. Expert Opin Biol Ther. 2018;18(12):1257-1270. https://doi.org/10.1080/14712598.2018.1545836
  22. Sun C, Zhang H, Jiang J, Li Y, Nie C, Gu J, et al. Angiogenic and inflammatory biomarker levels in aqueous humor and vitreous of neovascular glaucoma and proliferative diabetic retinopathy. Int Ophthalmol. 2020;40(2): 467-475.  https://doi.org/10.1007/s10792-019-01207-4
  23. Sun C, Zhang H, Tang Y, Chen Y, Li Y, Nie C, et al. Aqueous inflammation and ischemia-related biomarkers in neovascular glaucoma with stable iris neovascularization. Curr Eye Res. 2020;45(12):1504-1513. https://doi.org/10.1080/02713683.2020.1762226
  24. Boss JD, Singh PK, Pandya HK, Tosi J, Kim C, Tewari A, et al. Assessment of neurotrophins and inflammatory mediators in vitreous of patients with diabetic retinopathy. Invest Ophthalmol Vis Sci. 2017;58(12):5594-5603. https://doi.org/10.1167/iovs.17-21973
  25. Abcouwer SF. Müller cell-microglia cross talk drives neuroinflammation in diabetic retinopathy. Diabetes. 2017;66(2):261-263.  https://doi.org/10.2337/dbi16-0047
  26. Zhang A, Ning L, Han J, Ma Y, Ma Y, Cao W, et al. Neutrophil-To-Lymphocyte ratio as a potential biomarker of neovascular glaucoma. Ocul Immunol Inflammation. 2021;29(2):417-424.  https://doi.org/10.1080/09273948.2019.1677916
  27. Ulu SM, Dogan M, Ahsen A, Altug A, Demir K, Acartürk G, et al. Neutrophil-to-lymphocyte ratio as a quick and reliable predictive marker to diagnose the severity of diabetic retinopathy. Diabetes Technol Ther. 2013;15(11): 942-947.  https://doi.org/10.1089/dia.2013.0097
  28. Kern TS, Miller CM, Du Y, Zheng L, Mohr S, Ball SL, et al. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes. 2007;56(2):373-379.  https://doi.org/10.2337/db05-1621
  29. Sora D, Takayama K, Taguchi M, Sato T, Sakurai Y, Kanda T, et al. Topical corticosteroid-resolved rubeosis iridis with neovascular glaucoma caused by noninfectious granulomatous uveitis. Case Rep Ophthalmol. 2018;9(1): 243-247.  https://doi.org/10.1159/000488137
  30. Ajvazi H, Lutaj P. Clinical impact in the management of neovascular glaucoma. Rom J Ophthalmol. 2015;59(3):154-158. 
  31. European Glaucoma society terminology and guidelines for glaucoma, 4th edition — chapter 2: Classification and terminologySupported by the EGS foundation: Part 1: Foreword; introduction; glossary; chapter 2 classification and terminology. Br J Ophthalmol. 2017;101(5):73-127.  https://doi.org/10.1136/bjophthalmol-2016-EGSguideline.002
  32. Senthil S, Chary R, Ali MH, Cherukuri JR, Rani PK, Krishnamurthy R, et al. Trabeculectomy for neovascular glaucoma in proliferative diabetic retinopathy, central retinal vein occlusion, and ocular ischemic syndrome: Surgical outcomes and prognostic factors for failure. Indian J Ophthalmol. 2021; 69(11):3341-3348. https://doi.org/10.4103/ijo.IJO_1516_21
  33. Reddy S, Doshi S, Pathengay A, Panchal B. Ocular decompression retinopathy following intracameral bevacizumab injection in a case of proliferative diabetic retinopathy with neovascular glaucoma. Indian J Ophthalmol. 2020; 68(6):1206-1209. https://doi.org/10.4103/ijo.IJO_1401_19
  34. SooHoo JR, Seibold LK, Pantcheva MB, Kahook MY. Aflibercept for the treatment of neovascular glaucoma. Clin Exp Ophthalmol. 2015;43(9):803-807.  https://doi.org/10.1111/ceo.12559
  35. Zhou M, Xu X, Zhang X, Sun X. Clinical outcomes of ahmed glaucoma valve implantation with or without intravitreal bevacizumab pretreatment for neovascular glaucoma: A systematic review and meta-analysis. J Glaucoma. 2016;25(7):551-557.  https://doi.org/10.1097/IJG.0000000000000241
  36. Sivak-Callcott JA, O’Day DM, Gass JD, Tsai JC. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology. 2001;108(10):1767-1776. https://doi.org/10.1016/S0161-6420(01)00775-8
  37. Dumbraveanu L, Cușnir V, Bobescu D. A review of neovascular glaucoma. Etiopathogenesis and treatment. Romanian J Ophthalmol. 2021;65(4): 315-329.  https://doi.org/10.22336/rjo.2021.66.
  38. Havens SJ, Gulati V. Neovascular glaucoma. Dev Ophthalmol. 2015;55: 196-204.  https://doi.org/10.1159/000431196
  39. Nakamura Y, Takeda N, Mochizuki M. A case of vasoproliferative retinal tumor complicated by neovascular glaucoma. Retin Cases Brief Rep. 2013;7(4): 338-342.  https://doi.org/10.1097/ICB.0b013e3182598eea
  40. Zhou Q, Liang J, Lu H. Intravitreal bevacizumab for ocular metastasis of multiple myeloma. Optom Vis Sci. 2013;90(9):236-240.  https://doi.org/10.1097/OPX.0b013e31829caaf7
  41. Hong CH, Arosemena A, Zurakowski D, Ayyala RS. Glaucoma drainage devices: a systematic literature review and current controversies. Surv Ophthalmol. 2005;50(1):48-60.  https://doi.org/10.1016/j.survophthal.2004.10.006
  42. Iliev ME, Gerber S. Long-term outcome of trans-scleral diode laser cyclophotocoagulation in refractory glaucoma. Br J Ophthalmol. 2007;91(12): 1631-1635. https://doi.org/10.1136/bjo.2007.116533
  43. Ghosh S, Singh D, Ruddle JB, Shiu M, Coote MA, Crowston JG. Combined diode laser cyclophotocoagulation and intravitreal bevacizumab (Avastin) in neovascular glaucoma. Clin Exp Ophthalmol. 2010;38(4):353-357.  https://doi.org/10.1111/j.1442-9071.2010.02285.x
  44. Tan AM, Chockalingam M, Aquino MC, Lim ZI, See JL, Chew PT. Micropulse transscleral diode laser cyclophotocoagulation in the treatment of refractory glaucoma. Clin Exp Ophthalmol. 2010;38(3):266-272.  https://doi.org/10.1111/j.1442-9071.2010.02238.x
  45. Souissi S, Baudouin C, Labbe A, Hamard P. Micropulse transscleral cyclophotocoagulation using a standard protocol in patients with refractory glaucoma naive of cyclodestruction. Eur J Ophthalmol. 2021;31(1):112-119.  https://doi.org/10.1177/1120672119877586
  46. Zaarour K, Abdelmassih Y, Arej N, Cherfan G, Tomey KF, Khoueir Z. Outcomes of micropulse transscleral cyclophotocoagulation in uncontrolled glaucoma patients. J Glaucoma. 2019;28(3):270-275.  https://doi.org/10.1097/IJG.0000000000001174
  47. Zemba M, Dumitrescu O-M, Vaida F, Dimirache E-A, Pistolea I, Stamate AC, et al. Micropulse vs. continuous wave transscleral cyclophotocoagulation in neovascular glaucoma. Exp Ther Med. 2022;23(4):278.  https://doi.org/10.3892/etm.2022.11207
  48. Vasudev D, Blair MP, Galasso J, Kapur R, Vajaranant T. Intravitreal bevacizumab for neovascular glaucoma. J Ocul Pharmacol Ther. 2009;25(5): 453-458.  https://doi.org/10.1089/jop.2009.0036
  49. Brouzas D, Charakidas A, Moschos M, Koutsandrea C, Apostolopoulos M, Baltatzis S. Bevacizumab (Avastin) for the management of anterior chamber neovascularization and neovascular glaucoma. Clin Ophthalmol. 2009;3: 685-688.  https://doi.org/10.2147/opth.s7698
  50. Putera I, Suryono AN, Artini W. Challenging Management of Neovascular Glaucoma to Achieve the Best Visual Outcome. Case Rep Ophthalmol. 2020; 11(1):85-91.  https://doi.org/10.1159/000506041
  51. Chen HJ, Wang CG, Dou HL, Feng XF, Xu YM, Ma ZZ. Effect of intravitreal ranibizumab pretreatment on vitrectomy in young patients with proliferative diabetic retinopathy. Ann Palliat Med. 2020;9(1):82-89.  https://doi.org/10.21037/apm.2020.01.10
  52. Shen X, Chen Y, Wang Y, Yang L, Zhong Y. Intravitreal Ranibizumab Injection as an Adjuvant in the Treatment of Neovascular Glaucoma Accompanied by Vitreous Hemorrhage after Diabetic Vitrectomy. J Ophthalmol. 2016;4108490. https://doi.org/10.1155/2016/4108490
  53. Sun JT, Liang HJ, An M, Wang DB. Efficacy and safety of intravitreal ranibizumab with panretinal photocoagulation followed by trabeculectomy compared with Ahmed glaucoma valve implantation in neovascular glaucoma. Int J Ophthalmol. 2017;10(3):400-405.  https://doi.org/10.18240/IJO.2017.03.12
  54. Lyssek-Boroń A, Wylęgała A, Dobrowolski D, Kowalczyk E, Polanowska K, Wylęgała E. Evaluation of EX-PRESS glaucoma implant in elderly diabetic patients after 23G vitrectomy. Clin Intervent Aging. 2017;12:653-658.  https://doi.org/10.2147/CIA.S128618
  55. Petrachkov DV, Korobov EN, Arzhukhanov DD. Role of Vitrectomy in the Treatment of Diabetic Retinopathy. Oftal’mologiya. 2021;18(3S):718-726. (In Russ.). https://doi.org/10.18008/1816-5095-2021-3S-718-726
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.